Wolfgang Andreas Weber

Wolfgang Andreas Weber's AcademicInfluence.com Rankings

Computer Science

#4671

World Rank

#4930

Historical Rank

Computational Linguistics

#495

World Rank

#503

Historical Rank

Machine Learning

#993

World Rank

#1008

Historical Rank

Artificial Intelligence

#1214

World Rank

#1236

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Wolfgang Andreas Weber Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wolfgang Andreas Weber's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 (2014) (1949)
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. (2007) (1335)
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 (2009) (1255)
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging (2007) (778)
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. (2007) (774)
Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography (2001) (546)
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. (2000) (515)
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. (2003) (508)
Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD (2005) (494)
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. (2006) (459)
Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. (1999) (458)
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. (2004) (456)
Impact of animal handling on the results of 18F-FDG PET studies in mice. (2006) (453)
Reproducibility of metabolic measurements in malignant tumors using FDG PET. (1999) (426)
Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. (2001) (414)
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. (2001) (409)
Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography (2001) (383)
O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study (2000) (361)
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. (1998) (355)
Use of PET for monitoring cancer therapy and for predicting outcome. (2005) (354)
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. (2004) (345)
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. (2003) (329)
Tumor Cell Metabolism Imaging (2008) (316)
FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings (2003) (315)
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT (2017) (310)
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. (2004) (306)
Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man (2006) (303)
Positron emission tomography as an imaging biomarker. (2006) (295)
TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. (2008) (294)
Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. (2005) (271)
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo (2015) (256)
Assessing Tumor Response to Therapy (2009) (253)
Biodistribution and Pharmacokinetics of the αvβ3-Selective Tracer 18F-Galacto-RGD in Cancer Patients (2005) (247)
The EANM practice guidelines for bone scintigraphy (2016) (244)
L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. (2005) (233)
PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference (2011) (216)
Anesthesia and other considerations for in vivo imaging of small animals. (2008) (213)
Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. (1996) (212)
An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. (2011) (210)
Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors (2006) (205)
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study (2014) (191)
Positron Emission Tomography for Radiation Treatment Planning (2005) (190)
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. (2001) (188)
Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy (2018) (184)
Breast imaging with fluorine-18-FDG PET: quantitative image analysis. (1997) (183)
Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. (2006) (177)
Quantitative F18‐fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign (2010) (176)
Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas (2008) (176)
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. (2019) (173)
Monitoring response to treatment in patients utilizing PET. (2005) (172)
Relevance of Positron Emission Tomography (PET) in Oncology (1999) (169)
Biological imaging in radiation therapy: role of positron emission tomography (2009) (166)
Repeatability of 18F-FDG Uptake Measurements in Tumors: A Metaanalysis (2012) (166)
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible (2011) (163)
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas (2009) (163)
Quantitative assessment of tumor metabolism using FDG-PET imaging. (2000) (159)
[18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism (2012) (157)
Monitoring cancer treatment with PET/CT: does it make a difference? (2007) (143)
PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. (2006) (141)
Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study (2008) (140)
Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. (2005) (140)
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer (2007) (138)
O-(2-[18F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes (2002) (138)
Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas (2011) (137)
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting (2019) (131)
Novel 64Cu- and 68Ga-Labeled RGD Conjugates Show Improved PET Imaging of ανβ3 Integrin Expression and Facile Radiosynthesis (2011) (131)
Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men (2014) (130)
Reliability of PET/CT Shape and Heterogeneity Features in Functional and Morphologic Components of Non–Small Cell Lung Cancer Tumors: A Repeatability Analysis in a Prospective Multicenter Cohort (2016) (128)
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine (2019) (127)
Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy (2019) (126)
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (123)
Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. (2005) (122)
Monitoring chemotherapy and radiotherapy of solid tumors (2006) (122)
Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. (2012) (120)
Preoperative Evaluation of Pancreatic Masses with Positron Emission Tomography Using 18F-fluorodeoxyglucose: Diagnostic Limitations (2000) (118)
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications (2012) (117)
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. (2006) (117)
Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04 (2019) (115)
Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning (2008) (114)
Molecular imaging in the development of cancer therapeutics. (2006) (113)
Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. (2004) (111)
Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. (2005) (111)
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. (2005) (110)
Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas (2008) (108)
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer (2014) (108)
Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors (2008) (107)
Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction (2007) (107)
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. (2005) (105)
Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors (2008) (104)
Performance of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography and Integrated PET/CT in Restaged Breast Cancer Patients (2005) (104)
Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. (2003) (104)
Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET (2004) (103)
Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. (1997) (103)
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma (2018) (103)
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments (2017) (101)
[18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. (2011) (101)
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. (2018) (98)
Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. (2007) (97)
PET for radiation treatment planning of brain tumours. (2010) (96)
Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules (1998) (95)
Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B (2011) (95)
The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. (1998) (94)
[German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids]. (2011) (94)
11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. (2006) (93)
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake (2016) (93)
18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib (2011) (90)
Repeatability of 18F-FDG PET/CT in Advanced Non–Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials (2015) (88)
Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. (2016) (86)
Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. (2008) (85)
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. (2020) (85)
Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma (2008) (85)
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs (2008) (83)
First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas. (2000) (82)
Imaging of tumor glucose utilization with positron emission tomography (2008) (82)
Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells (2014) (82)
Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies (2018) (82)
Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. (2005) (82)
Imaging of esophageal and gastric cancer. (2004) (81)
Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100. (2013) (80)
Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years (2014) (80)
Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. (2005) (80)
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer (2018) (78)
Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. (2013) (76)
Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83. (2011) (76)
18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy (2012) (75)
Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. (2002) (73)
Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. (2015) (73)
(18)F-labeled-bioorthogonal liposomes for in vivo targeting. (2013) (73)
Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer (2017) (72)
Consensus on molecular imaging and theranostics in prostate cancer. (2018) (70)
Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. (1999) (70)
Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy (2018) (68)
Target engagement imaging of PARP inhibitors in small-cell lung cancer (2018) (67)
Tumor angiogenesis targeting using imaging agents. (2001) (66)
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models (2016) (66)
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine. (2018) (66)
Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin (2013) (65)
Radiotracer-based strategies to image angiogenesis. (2003) (65)
Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. (2019) (63)
FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer. (2015) (61)
Measuring response with FDG-PET: methodological aspects. (2009) (60)
Imaging the Folate Receptor on Cancer Cells with 99mTc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging (2014) (60)
Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer (2017) (59)
Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma (2015) (59)
Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist 68Ga-RM2 And PET (2016) (57)
Molecular Imaging of Biomarkers in Breast Cancer (2016) (57)
qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT (2019) (57)
Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent (2016) (54)
Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1) (2016) (54)
Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence (2020) (54)
Molecular Imaging of Prostate Cancer. (2016) (53)
18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative? (2007) (52)
Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. (2009) (51)
Correlation Between Postoperative 3-[123I]Iodo-l-α-Methyltyrosine Uptake and Survival in Patients with Gliomas (2001) (51)
In Vivo Imaging of GLP-1R with a Targeted Bimodal PET/Fluorescence Imaging Agent (2014) (51)
Generating Evidence for Clinical Benefit of PET/CT in Diagnosing Cancer Patients (2011) (51)
Induction Chemotherapy in Barrett Cancer: Influence on Surgical Risk and Outcome (2007) (50)
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan (2019) (50)
Utility of PET in Breast Cancer. (1999) (50)
Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. (2004) (48)
PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging (2014) (48)
18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy (2019) (47)
Brown adipose tissue and nuclear medicine imaging. (2004) (47)
In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates. (2012) (46)
Radioiodinated PARP1 tracers for glioblastoma imaging (2015) (46)
Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen (2000) (45)
CXCR4 antagonists suppress small cell lung cancer progression (2016) (45)
Whole-body positron emission tomography in clinical oncology: Comparison between attenuation-corrected and uncorrected images (1997) (45)
Monitoring Tumor Response to Therapy with 18F-FLT PET (2010) (44)
Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. (2016) (44)
European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. (2008) (43)
FDG/PET-CT-Based Lymph Node Atlas in Breast Cancer Patients. (2019) (42)
Use of the norepinephrine transporter as a reporter gene for non‐invasive imaging of genetically modified cells (2004) (42)
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. (2020) (41)
Engineered Antibody Fragments with Infinite Affinity as Reporter Genes for PET Imaging (2008) (41)
3′‐deoxy‐3′‐[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma (2012) (39)
Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide? (2016) (39)
Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer (2019) (39)
Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An 18F-FDG PET Study (2015) (39)
Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT (2017) (38)
Cerenkov Luminescence Imaging for Radiation Dose Calculation of a 90Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist (2015) (38)
PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma (2018) (38)
Correlation of the Genotype of Paragangliomas and Pheochromocytomas with Their Metabolic Phenotype on 3,4-Dihydroxy-6-18F-Fluoro-l-Phenylalanin PET (2012) (37)
Role of radionuclide imaging in trials of antiangiogenic therapy. (2000) (37)
Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors (2018) (37)
Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography. (2014) (36)
Derivation of a Compartmental Model for Quantifying 64Cu-DOTA-RGD Kinetics in Tumor-Bearing Mice (2009) (35)
Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist (2017) (35)
Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. (2019) (35)
How to study optimal timing of PET/CT for monitoring of cancer treatment. (2011) (35)
PET for response assessment in oncology: radiotherapy and chemotherapy (2005) (35)
Quantitative analysis of PET studies. (2010) (34)
18F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma (2013) (34)
11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. (2007) (34)
PET-Based Human Dosimetry of 18F-Galacto-RGD, a New Radiotracer for Imaging avb3 Expression (2006) (33)
Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 68Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques (2019) (33)
Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients (2021) (32)
PET imaging with [11C]methyl-L-methionine for therapy monitoring in patients with rectal cancer (2002) (32)
Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview (2017) (31)
Fluorodeoxyglucose-Positron Emission Tomography in Adenocarcinomas of the Distal Esophagus and Cardia (2003) (31)
Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes (2018) (31)
Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non–Tumor-Related Uptake and Tumor Positivity (2020) (30)
Does Imaging αvβ3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy? (2014) (30)
Histologically Confirmed Diagnostic Efficacy of 18F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer (2019) (30)
Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling (2016) (30)
Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. (1996) (29)
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0 (2022) (29)
PET with 18F-fluorodeoxyglucose for staging of non-small cell lung cancer (2003) (28)
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma (2021) (28)
Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer (2019) (28)
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas (2009) (28)
Influence of experience and qualification on PET-based target volume delineation (2014) (28)
Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. (2001) (27)
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. (2020) (27)
18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors (2019) (27)
18F-FDG PET Is an Early Predictor of Overall Survival in Suspected Atypical Parkinsonism (2015) (27)
PET/MR Imaging: A Critical Appraisal (2014) (27)
FDG-PET lymphoma demonstration project invitational workshop. (2007) (27)
T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target (2018) (26)
11C-Choline PET/pathology image coregistration in primary localized prostate cancer (2014) (26)
Development of a clickable bimodal fluorescent/PET probe for in vivo imaging (2015) (26)
Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma (2016) (26)
89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo (2019) (25)
The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST (2016) (25)
Image Quality and Data Quantification in Dopamine Transporter SPECT: Advantage of 3-Dimensional OSEM Reconstruction? (2012) (25)
Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04 (2021) (25)
Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer. (2015) (25)
Irradiation of regional lymph node areas in breast cancer - Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design. (2019) (25)
Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer (2018) (25)
CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma (2020) (24)
Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (2020) (24)
Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas (2020) (24)
Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. (2019) (24)
Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET (2018) (24)
The Move from Accuracy Studies to Randomized Trials in PET: Current Status and Future Directions (2014) (24)
Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma (2017) (24)
Stereotactic ablative radiotherapy for small lung tumors with a moderate dose (2012) (24)
The Controversial Linear No-Threshold Model (2017) (24)
A Predictive Model for Lymph Node Involvement with Malignancy on PET/CT in Non–Small-Cell Lung Cancer (2015) (24)
Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. (2017) (24)
Activated Platelets in Carotid Artery Thrombosis in Mice Can Be Selectively Targeted with a Radiolabeled Single-Chain Antibody (2011) (23)
FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus (2005) (23)
Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed? (2014) (23)
Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. (2021) (23)
Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent (2017) (22)
Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy (2016) (22)
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study (2022) (21)
18F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer (2003) (21)
The added value of PSMA PET/MR radiomics for prostate cancer staging (2021) (21)
In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. (2011) (20)
Joint Imaging Platform for Federated Clinical Data Analytics (2020) (20)
Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy—results from a prospective trial (2019) (19)
Development of a New Folate-Derived Ga-68-Based PET Imaging Agent (2017) (19)
Preferred transport of O-(2-[18F]fluoroethyl)-d-tyrosine (d-FET) into the porcine brain (2007) (18)
Validation of a method for automatic image fusion of CT-data and C11-methionin-PET data for stereotactic radiotherapy using a LINAC (BrainLAB System). First clinical results (2002) (18)
Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications (2020) (18)
Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study (2018) (18)
2017 SNMMI Highlights Lecture: Oncology. (2018) (18)
Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes (2020) (18)
Trends in oncologic hybrid imaging (2018) (18)
FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma (2014) (18)
Amyloid-β Load Predicts Medial Temporal Lobe Dysfunction in Alzheimer Dementia (2013) (18)
Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy (2017) (17)
Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer (2018) (17)
PET and SPECT for radiation treatment planning. (2012) (17)
Metabolic Imaging Allows Early Prediction of Response to Vandetanib (2011) (17)
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma. (2017) (17)
Excretion of FDG into saliva and its significance for PET imaging (2002) (17)
Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines (2019) (17)
Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation (2020) (17)
Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists (2018) (17)
Chaperoning drug development with PET. (2006) (16)
PET/CT molecular imaging in abdominal oncology (2004) (16)
Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy (2020) (15)
Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection? (2019) (15)
An official ATS conference proceedings: advances in small-animal imaging application to lung pathophysiology. (2008) (15)
PET/CT is a cost-effective tool against cancer: synergy supersedes singularity (2016) (15)
Small-Animal PET/CT for Monitoring the Development and Response to Chemotherapy of Thymic Lymphoma in Trp53−/− Mice (2010) (15)
Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib (2018) (15)
Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. (2006) (15)
How to use functional imaging information for radiotherapy planning. (2009) (15)
Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? (2017) (14)
An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients (2016) (14)
A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas (2018) (14)
Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome (2019) (14)
UvA-DARE ( Digital Academic Repository ) FDG PET and PET / CT : EANM procedure guidelines for tumour PET imaging : version 1 (2009) (13)
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria (2022) (13)
Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (NIS) gene expression using a heat-inducible gene promoter in engineered mesenchymal stem cells (2020) (13)
11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series (2019) (13)
Evaluation of the GRPR radioantagonist Cu-64-CB-TE2A-AR-06 in mice and men (2011) (13)
Is There Evidence for Evidence-Based Medical Imaging? (2011) (12)
The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts (2012) (12)
Rates and equilibria for probe capture by an antibody with infinite affinity. (2010) (12)
Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma (2019) (12)
New tracers beyond FDG in head and neck oncology. (2011) (12)
A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer (2020) (12)
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment. (2021) (12)
Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models (2018) (12)
Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial (2020) (12)
Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer (2016) (12)
Synthesis and Preclinical Evaluation of a 68 Ga-Labeled Adnectin, 68 Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression (2021) (12)
First In-Human Medical Imaging with a PASylated 89Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer (2020) (11)
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial (2021) (11)
Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression (2021) (11)
First clinical evaluation of somatostatin receptor antagonist imaging (2010) (11)
Positron‐emission tomography imaging in urological oncology: Current aspects and developments (2018) (11)
32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts (2017) (11)
Regional hyperthermia enhances mesenchymal stem cell recruitment to tumor stroma: Implications for mesenchymal stem cell-based tumor therapy. (2020) (11)
[18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases. (2012) (10)
Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (89Zr)-DFO- Galectin3-F(ab')2 mAb (2021) (10)
Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy (2020) (10)
Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T (2020) (10)
Utility of FDG-PET in immunotherapy: results from a Phase II study of NSCLC patients undergoing therapy with the PD-L1 inhibitor, atezolizumab (MPDL3280A) (2016) (10)
Neuronal Correlates of Clinical Asymmetry in Progressive Supranuclear Palsy (2014) (10)
PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial. (2019) (9)
Evaluation of the Efficacy of Targeted Imaging Agents (2016) (9)
Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning (2021) (9)
The AQARA Principle: Proposing Standard Requirements for Radionuclide-Based Images in Medical Journals (2020) (9)
Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment (2020) (9)
Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions (2021) (9)
Correction to: 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors (2019) (9)
Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201. (2017) (9)
O-(2-(18F)Fluorethyl)-L-Tyrosine Compared to L-(Methyl-11C) Methionine in Positron Emissions Tomography for Tumor Volume Delineation of Gliomas and Metastases (2005) (8)
OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers (2017) (8)
11C-Choline Pharmacokinetics in Recurrent Prostate Cancer (2018) (8)
Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis (2019) (8)
Al18F labeling at room temperature of 2-aminomethylpiperidine-based chelators for PET imaging. (2019) (8)
Small Data: A Ubiquitous, Yet Untapped, Resource for Low-Cost Imaging Innovation (2017) (8)
Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer (2021) (8)
Pitfalls in Ga-68-PSMA-PET/CT: incidental finding of parathyroid adenoma (2019) (8)
Value of PET imaging for radiation therapy (2021) (8)
Value of PET imaging for radiation therapy (2021) (8)
Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy (2022) (8)
Synthesis and Evaluation of a Novel 64Cu- and 67Ga-Labeled Neurokinin 1 Receptor Antagonist for in Vivo Targeting of NK1R-Positive Tumor Xenografts. (2018) (8)
What Is the Clinical Value of PET/CT in the Diagnosis of Pulmonary Nodules? (2014) (7)
Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors. (2018) (7)
123I-Iodobenzamide SPECT Is Not an Independent Predictor of Dopaminergic Responsiveness in Patients with Suspected Atypical Parkinsonian Syndromes (2013) (7)
Individualized neoadjuvant treatment strategy in adenocarcinoma of the esophago-gastric junction (AEG): Interim report on the MUNICON trial. (2004) (7)
Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients (2021) (7)
Selective sodium iodide symporter (NIS) genetherapy of glioblastoma mediatedby EGFR-targeted lipopolyplexes (2021) (7)
Development of a chimeric Fab directed against human galectin-3 and validation as an immune-PET tracer for the sensitive in vivo imaging of thyroid cancer. (2020) (7)
Clinical PET/MR. (2020) (7)
Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer (2022) (6)
A 3D Deep Residual Convolutional Neural Network for Differential Diagnosis of Parkinsonian Syndromes on 18F-FDG PET Images (2019) (6)
Issues and controversies in nuclear medicine. Introduction. (2011) (6)
Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer (2017) (6)
Role of Molecular Imaging in the Era of Personalized Medicine: A Review (2014) (6)
Driving the Future of Nuclear Medicine (2019) (6)
Neuroimaging for Radiation Therapy of Brain Tumors (2019) (6)
Detection Efficacy of 18F‐rhPSMA‐7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment (2021) (6)
CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma (2019) (6)
Room Temperature Al18F Labeling of 2‐Aminomethylpiperidine‐Based Chelators for PET Imaging (2020) (6)
Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic (2021) (6)
Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET (2007) (6)
GRPR antagonist 68Ga-RM2 as PET tracer for imaging prostate cancer: Initial experiences (2014) (5)
The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data (2021) (5)
Imaging CXCR4 Expression with Iodinated and Brominated Cyclam Derivatives (2020) (5)
Almost 10 years of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients (2020) (5)
Effect of specific activity on the uptake of [68Ga]-DKFZ-PSMA11 in tumor and other organs (2016) (5)
Reply: Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV (2015) (5)
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy (2021) (5)
Prognostic Significance of Fluorodeoxyglucose Uptake in Non–Small Cell Lung Cancer. A Blurry Picture? (2007) (5)
Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy—validation of a prediction model (2020) (5)
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET (2020) (5)
Influence of Animal Heating on PET Imaging Quantification and Kinetics: Biodistribution of 18F-Tetrafluoroborate and 18F-FDG in Mice (2017) (5)
Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting. (2019) (5)
Hybrid Imaging of Peripheral Skeletal Disease by SPECT/High-Resolution Flat-Panel CT (2013) (5)
Implementation of Cascade Gamma and Positron Range Corrections for I-124 Small Animal PET (2014) (5)
Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? (2017) (4)
Using Monte-Carlo simulations to implement corrections for I-124 as a non-pure positron emitter in small animal and human PET imaging (2011) (4)
Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer (2021) (4)
Tracked 3D ultrasound and deep neural network-based thyroid segmentation reduce interobserver variability in thyroid volumetry (2021) (4)
Influence of ROI definition on the results of FDG-PET studies in patients with sarcomas (2007) (4)
PET and SPECT in Three-Dimensional Treatment Planning of Brain Gliomas (2000) (4)
[Importance of FDG-PET/computed tomography in colorectal cancer]. (2019) (4)
Assessment of hypoxia in esophageal carcinomas using 18F-MISO PET (2008) (4)
Prognostic Value of metabolic parameters on Pretreatment F-18 FDG PET/CT in Patients with Advanced melanoma treated with Pembrolizumab (2019) (4)
Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT (2022) (4)
Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiation. (2006) (4)
Monitoring of Tumour Glucose Metabolism by PET in a Phase I Study Evaluating Hormonal Therapy in Advanced Pancreatic Cancer (2002) (4)
18 F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma (2013) (4)
Individualized indication for neoadjuvant treatment based on metabolic response Assessed by 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in adenocarcinoma of the esophago-gastric junction (AEG) (2005) (4)
18 F-Meta Fluorobenzyl Guanidine (MFBG) PET imaging in patients with Neuroendocrine malignancies: Biodistribution, Pharmacokinetics, Organ dosimetry and Lesion uptake. (2016) (3)
Imaging in Oncology Research (2011) (3)
Dynamics of Tumor Hypoxia in Patients undergoing Radiochemotherapy for Head and Neck Cancer Evaluated with Serial 18F-fluoromisonidazole PET (2010) (3)
Unilateral Suppression of Brown Fat on FDG PET/CT in Horner Syndrome. (2016) (3)
Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo (2021) (3)
The value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography for the treatment planning of malignant gliomas. (1999) (3)
Erratum to: Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer (2017) (3)
Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study (2020) (3)
FDG-PET/CT versus contrast enhanced CT for prediction of progression-free and disease-specific survival in stage IV breast cancer patients. (2015) (3)
Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients (2022) (3)
A Historical Perspective on the Use of Radionuclides for Therapy (2013) (3)
mutation and glucose metabolism in thyroid cancer patients : An 18 F-FDG-PET study (2015) (3)
Zr-J 591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (3)
Assessment of Striatal Dopamine D2/D3 Receptor Availability with PET and 18F-Desmethoxyfallypride: Comparison of Imaging Protocols Suited for Clinical Routine (2012) (3)
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer (2022) (3)
Temporary Reactive Response of Axillary Lymph Nodes to COVID-19 Vaccination on 18F-rhPSMA-7.3 PET/CT in Patients with Prostate Cancer (2022) (3)
177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers (2022) (3)
The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy (2022) (3)
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3 (2022) (2)
Use of 68Ga-DOTA-TATE PET/CT for predicting the dose of 177Lu-DOTA-TATE therapy in patients with neuroendocrine tumors (NETs) (2012) (2)
LETTER TO THE EDITOR: Reply from the Authors: (2003) (2)
Noninvasive Imaging of A V B 3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib (2009) (2)
PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK). (2022) (2)
Prediction of tumour response by FDG-PET in patients with adenocarcinomas of the oesophagogastric junction (2008) (2)
Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma (2022) (2)
2016 SNMMI Highlights Lecture: Oncology, Part 1. (2017) (2)
RSV: Robotic Sonography for Thyroid Volumetry (2021) (2)
In Vivo Testing of 177 Lu-Labelled Anti-PSMA Antibody as a New Radioimmunotherapeutic Agent Against Prostate Cancer (2011) (2)
Predictive value of interim PSMA PET during 177Lu-PSMA radioligand therapy for overall survival in patients with advanced prostate cancer (2019) (2)
[68Ga-PSMA-11 PET/mpMRI for local detection of primary prostate cancer in men with a negative prior biopsy]. (2020) (2)
Monitoring neoadjuvant chemotherapy of bone and soft tissue sarcomas with FDG-PET/CT (2006) (2)
Novel Low-Dose CT based Automatic Segmentation and Registration Framework for Liver Radioembolization Planning (2021) (2)
Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard (2020) (2)
SNMMI Highlights Lecture : Oncology (2017) (2)
Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. (2020) (2)
Mixed response on FDG PET/CT: Frequency and prognostic relevance in non-small cell lung cancer (NSCLC) (2014) (2)
MO-DE-207B-11: Reliability of PET/CT Radiomics Features in Functional and Morphological Components of NSCLC Lesions: A Repeatability Analysis in a Prospective Multicenter Cohort. (2016) (2)
Abstract CT140: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies (2018) (2)
A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa). (2016) (2)
Change in quantitative FDG-PET was significantly more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high grade soft tissue sarcomas (2007) (2)
Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer (2019) (2)
Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma (2022) (2)
Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicity. (2007) (2)
Emerging molecular imaging targets and tools for myocardial fibrosis detection (2022) (2)
Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA (2019) (2)
Prognostic value of total lesion glycolysis on pretreatment F-18 FDG PET/CT in patients with advanced NSCLC treated with nivolumab (2018) (2)
[18F]Fluorodeoxyglucose Positron Emission Tomography Assessment of Response (2007) (2)
Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study. (2021) (2)
In vivo Visualization of M2 Macrophages in the Myocardium After Myocardial Infarction (MI) Using 68Ga-NOTA-Anti-MMR Nb: Targeting Mannose Receptor (MR, CD206) on M2 Macrophages (2022) (2)
Correction to: Value of PET imaging for radiation therapy (2021) (1)
Comparison of SUVmax and SUVpeak for response assessment in stage 4 non-small cell lung cancer (NSCLC) by FDG PET/CT (2015) (1)
Correction to: Value of PET imaging for radiation therapy (2021) (1)
Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis (2022) (1)
89Zr-IAB2M minibody imaging in patients with prostate cancer: Biodistribution, kinetics, lesion uptake and organ dosimetry (2014) (1)
Positron Emission Tomography: Significance for Preoperative N-Staging (2005) (1)
Does the Injected Mass influence the Biodistribution of F-18-rhPSMA-7.3 on Positron Emission Tomography in Prostate Cancer Patients? (2020) (1)
PET imaging of inflammatory processes during GvHD (2011) (1)
2694 : Delayed Administration of Growth Factors in a Mouse Model of Radiation-Induced Kidney Dysfunction (2006) (1)
Change of tumor cell proliferation during R-CHOP chemotherapy of diffuse large B cell lymphoma (DLBCL) measured by 18FLT-PET (2006) (1)
Targeted imaging of NK1 receptor-expressing cancer with 64Cu-labeled new NK1 ligand (2015) (1)
Tracked 3D ultrasound and deep neural network-based thyroid segmentation improve accuracy and interobserver variability in thyroid volumetry (2021) (1)
First clinical evidence that radiolabeled somatostatin receptor antagonist may be preferable to agonists for the treatment of neuroendocrine tumors (2012) (1)
Inhibitor-functionalized ultrasmall nanoparticles and methods thereof (2017) (1)
Quantification of PSMA expression in primary human and xenograft tumors using radioligand binding and digital autoradiograpy (2015) (1)
Nuclear Molecular Imaging of Cardiac Remodeling after Myocardial Infarction (2022) (1)
18F-rhPSMA7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy (2019) (1)
Metabolic imaging predicts response and prognosis in neoadjuvant treated, locally advanced gastric cancer: Final results of a prospective study (2007) (1)
Are radiolabeled GLP-1 receptor antagonists useful for scintigraphy? (2009) (1)
305 TUMOR HYPOXIA IN HEAD AND NECK CANCER DURING RADIOCHEMOTHERAPY EVALUATED WITH SERIAL [18F] -FLUOROMISONIDAZOLE PET (2012) (1)
The value of IMT-SPECT investigation in the target volume definition of brain gliomas (1998) (1)
Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors (2022) (1)
2016 SNMMI Highlights Lecture: Oncology, Part 2. (2017) (1)
Reply: Eliminating Use of the Linear No-Threshold Assumption in Medical Imaging (2017) (1)
7037 POSTER Radiopeptide Therapy of Prostate Cancer LU-177-RM2 (BAY 1017858) Monotherapy and in Combination With PKI Inhibitors (2011) (1)
Improved PET Imaging of a n b 3 Integrin Expression and Facile Radiosynthesis (2011) (1)
F-18 FDG PET/CT for monitoring immunotherapy with PD-1 blockade in patients with advanced melanoma (2019) (1)
A Phase I/II Study for Analytic Validation of Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (1)
Molecular imaging: dream or reality? (2001) (1)
Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines (2019) (1)
Validation of a method for automatic image fusion (BrainLAB System) of CT-data and C11-Methionin-PET data for stereotactic fractionated radiotherapy using a LINAC (2001) (1)
Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer: Final analysis. (2018) (1)
Value of PET imaging for radiation therapy (2021) (1)
Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET (2018) (1)
Diagnostic performance of different quantitative and qualitative parameters and their combined value for the diagnosis of aortic graft infection using [18F]-FDG PET/CT (2019) (1)
The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation (2022) (1)
Contrast improvement of FDG microPET studies by voxel-wise Patlak analysis (2010) (1)
Prognostic Impact of Early and Late 18fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Prior to Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed or Refractory Hodgkin Lymphoma (2011) (1)
Utility of Amino Acid PET in the Differential Diagnosis of Recurrent Brain Metastases and Treatment-Related Changes: A Meta-analysis (2022) (1)
Evaluation of insulin-like growth-factor-1 as a protective agent against radiation-induced kidney dysfunction in C3h mice: A dose-finding study (2004) (1)
FDG-PET for radiation treatment planning in patients with lung metastases (2010) (1)
Toward Novel [18F]Fluorine-Labeled Radiotracers for the Imaging of α-Synuclein Fibrils (2022) (1)
Performance of automatic Liver Volumetry for Selective Internal Radiotherapy (2021) (1)
Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020. (2023) (1)
2388 : Non-Invasive Imaging of Alpha-v-Beta-3-Expression in Head-and-Neck Cancer Patients With (18F)Galacto-RGD and Positron Emission Tomography (2006) (1)
Non‐invasive determination of the αvβ3 integrin expression using [18F]galacto‐RGD and pet (2001) (1)
Translational molecular imaging. (2004) (1)
Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy (2022) (1)
Evaluation of metabolic imaging for assessment of tumor response to mTOR inhibitors (2007) (0)
Quantitative FDG-PET is more accurate than CT size at differentiating malignant from benign peripheral nerve tumors (2008) (0)
Interobserver variability of assessment of tumor response by FDG-PET (2007) (0)
Introduction of semi-automatic whole-body tumor burden assessment in 68Ga-PSMA-11 PET/CT to predict outcome of PSMA-targeted radiologandtherapy (2018) (0)
PP69. Cost effectiveness of FDG-PET in the evaluation of solitary pulmonary nodules (1997) (0)
Multi-Reader Evaluation of Manual Tumor Delineation for Recurrent Glioblastoma on FET-PET Scan: Impact of PET Windowing Settings (2014) (0)
Multimodality imaging of cytostatic response to therapy in tumor-bearing mice (2007) (0)
Early prediction of response in patients with NSCLC stage III and IV during platin based chemotherapy by FDG-PET (2001) (0)
Abstract 3735: Somatostatin receptor-based imaging and treatment of murine pancreatic neuroendocrine tumors induced by MEN1-loss (2018) (0)
Differential Diagnosis of Parkinsonism with Deep Metabolic Imaging Biomarker – An Artificial Intelligence-Aided Multi-Cohort FDG PET Study (2020) (0)
Prospects for Molecular Imaging in Humans (2005) (0)
Using siRNA as a tool to dissect the molecular pathway for FDG uptake in tumor cells (2007) (0)
PD17-04 DIAGNOSTIC EFFICACY OF 18F-RHPSMA7 POSITRON EMISSION TOMOGRAPHY FOR N-STAGING OF PATIENTS WITH HIGH RISK PRIMARY PROSTATE CANCER (2019) (0)
Change of clinical management through serial FDG-PET/CT in patients with FDG-positive adverse events under immunotherapy (2019) (0)
68Ga-BMS-986192 as a PET Agent for Imaging PD-L1 Expression (2021) (0)
PSMA-ligand PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy: matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 (2019) (0)
EP-1313 PET-BASED GTV CONTOURING: WAYS FOR IMPROVEMENT OF THE INTER-OBSERVER VARIABILITY IN MANUAL CONTOURING (2012) (0)
129 The impact of I-123-alpha-methyl-tyrosine spect in the planning of 3-D radiation treatment of brain gliomas (1999) (0)
Effect of HNSCC Radiochemotherapy on Imaging Biomarker T2* MRI and its Relation to FMISO-PET Derived Hypoxia (2018) (0)
[18F]FDG-PET is an early predictor of overall survival in patients with suspected atypical parkinsonian syndromes. (2015) (0)
Reply: Radioguided Surgery (2021) (0)
Metabolic response-guided treatment individualization in neoadjuvant therapy of locally advanced adenocarcinoma of the esophagogastric junction (AEG) (2007) (0)
Treatment of Benign Meningiomas with Stereotactic Fractionated Radiotherapy (2005) (0)
Makes the Difference (2011) (0)
A compartmental model for kinetics of 64Cu-RGD peptide in mice (2008) (0)
Supporting Information for Dual Modality Optical / PET imaging of PARP 1 in Glioblastoma Journal : Molecular Imaging and Biology (2015) (0)
Dual-modality imaging and quantification of GLP-1R positive insulinoma and pancreatic beta-cell mass using a bimodal PET/fluorescence exendin-4 peptide (2014) (0)
PH-0719: 18F-FDG-PET/CT parameters as predictors of survival and response to nCRT in esophageal cancer (2020) (0)
Local recurrence after radical prostatectomy and additive radiation – can PSMA-radioguided surgery prolong therapy-free survival? (2020) (0)
SP 112 Integration of metabolic imaging (PET CT) into clinical trials (2011) (0)
Lack of association between striatal dopamine receptor availability and cerebral glucose metabolism in PSP (2010) (0)
Glucagon-like peptide-1 receptor SPECT/CT for the preoperative localization of benign insulinomas (2012) (0)
Target engagement imaging of PARP inhibitors in small-cell lung cancer (2018) (0)
PO-0793 EXPERT PANEL REVIEW OF FDG-PET/CT IN NSCLC: IMPROVEMENT OF INTER-, INTRAOBSERVER VARIABILITY BY HARMONIZATION (2012) (0)
15O-H2O-PET analysis of blood flow in esophageal cancer (2008) (0)
Radiopeptide therapy of prostate cancer with a bombesin antagonist combined with vasculature targeted photodynamic therapy (2014) (0)
Tumor FDG-uptake after the initial cycle of chemotherapy and histopathologic response to neoadjuvant therapy in high-grade soft tissue sarcomas (2008) (0)
External in-house validation of a prediction nomogram estimating pre-test 68 Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy (2020) (0)
Wholebody Clearance Of Three 89Zr Labeled Antibodies:Differences between PET based and Whole Body Probe Based Clearance (2015) (0)
2017 SNMMI Highlights Lecture: Oncology, Part 2. (2018) (0)
Reproducibility of FDG microPET, Firefly and Renilla luciferase bioluminescence imaging measurements in tumor bearing mice (2006) (0)
IMT-SPECT in brain gliomas: correlation with survival and consequences for irradiation treatment planning (2001) (0)
Cerenkov luminescence imaging for radiation dose estimation of a 90Y-labeled GRPr antagonist (2014) (0)
Imaging of regional cerebral glucose metabolism is superior to assessment of striatal dopamine D2/D3 receptors for the differential diagnosis of parkinsonism: A prospective PET and SPECT study (2012) (0)
Inside Cover: From In Situ to In Vivo: An In Situ Click‐Chemistry‐Derived Carbonic Anhydrase II Imaging Agent for Positron Emission Tomography (ChemMedChem 1/2013) (2013) (0)
High resolution reconstruction of whole body FDG PET studies (2012) (0)
Breast I maging W ith P ositron E mission T omography a nd Fluorine-18 F luorodeoxygluco se: U se a nd L imitations (2000) (0)
Inhomogeneous PET/CT-FDG response to therapy in metastatic breast cancer (2014) (0)
Influence of animal heating on PET imaging quantification and kinetics: results on the biodistribution of 18 F-tetrafluoroborate and 18 F-FDG in mice (2016) (0)
In situ click chemistry approach for the identification of carbonic anhydrase II and cyclooxygenase-2 PET imaging agents (2006) (0)
103 poster: Use of FDG-4D-PET-CT for the Delineation of Radiotherapy Target Volumes in Malignant Lung Lesions (2010) (0)
Unexpected sensitivity of SST2 antagonists to radiometal modifications (2012) (0)
Noninvasive Imaging ofavb3 Integrin Expression Using F-labeled RGD-containing Glycopeptide and Positron Emission Tomography (2001) (0)
Comparison of the distribution of lymph node metastases compared to healthy lymph nodes in breast cancer (2022) (0)
TM-15GLUTAMINE BASED PET IMAGING FACILITATES ENHANCED METABOLIC DETECTION OF GLIOMAS IN VIVO (2014) (0)
FDG PET/CT for the evaluation of patients with thyroid associated orbitopathy (2007) (0)
A Model of Experimental Kidney Irradiation for Screening of Response Modifiers: Evaluation of Insulin-like Growth Factor-1 (IGF-1) and Erythropoietin (EPO) (2005) (0)
Value of PET imaging for radiation therapy* Wertigkeit der PET-Bildgebung für die Radioonkologie (2021) (0)
Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal Adenocarcinoma (2021) (0)
Integrin αV Inhibition Reduces GvHD by Targeting inflammatory Neovascularization (2011) (0)
Synthesis and Preclinical Evaluation of Ga-68-labeled Adnectin as a PET Agent for Imaging PD-L1 Expression (2020) (0)
Future Directions The Move from Accuracy Studies to Randomized Trials in PET : Current Status and (2014) (0)
Detection Efﬁcacy of 18 F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy (2019) (0)
Development of a novel high affinity Zr-89-Anticalin radiotracer directed against human CD98hc for diagnostic PET tumor imaging (2020) (0)
Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients (2022) (0)
Detection efficacy in 261 consecutive biochemical recurrent prostate cancer patients after radical prostatectomy using 18F-rhPSMA7 PET/CT imaging (2019) (0)
Abstract B39: A pilot study of neuropsychological functions, APOE, and amyloid imaging in patients with gliomas (2018) (0)
PO-0969 4D-PET/CT FOR TARGET VOLUME DELINEATION IN STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR MALIGNANT LUNG LESIONS (2012) (0)
The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy. (2022) (0)
In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy (2021) (0)
Mesenchymal Stem Cell-mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice. (2022) (0)
Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma (2022) (0)
19 INVITED Application of Hypoxia Imaging in Radiation Treatment Planning (2011) (0)
MP62-17 DIAGNOSTIC EFFICACY OF 18 F-RHPSMA-7.3 IMAGING FOR N-STAGING PATIENTS WITH HIGH-RISK PROSTATE CANCER (2020) (0)
Monitoring bevacizumab therapy with PET/CT and 68Ga-NODAGA-c(RGDfK) (2013) (0)
Quantitative and qualitative analysis of biodistribution and image quality of 18F- rhPSMA7 as novel radiohybrid PSMA-ligand (2019) (0)
Nephrotoxicity after PSMA-RLT using Lu-177-PSMA I&T (2021) (0)
[Monitoring of response to neoadjuvant therapy by positron emission tomography (PET)]. (2001) (0)
Comparison of the distribution of lymph node metastases compared to healthy lymph nodes in breast cancer (2022) (0)
Integrating respiratory gating and continuous bed motion PET/CT: evaluating an improved clinical workflow (2019) (0)
qPSMA: First semi-automatic tool for whole-body tumor burden assessment in prostate cancer PET imaging and preliminary evaluation for PSMA-targeted radioligand therapy (2019) (0)
Diagnostic efficacy of 18F-rhPSMA7 positron emission tomography for lymph node staging in patients with high-risk primary prostate cancer (2019) (0)
Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET (2018) (0)
Influence of chemotherapy related genetic polymorphisms and FDG-PET on response and prognosis of locally advanced neoadjuvant treated adenocarcinomas of the esophagus (AEG I). (2006) (0)
Lesion Detection Efficacy of F-18-rhPSMA-7.3 Positron Emission Tomography in Men with Biochemical Recurrence of Prostate Cancer: Initial clinical data from 285 consecutive Patients (2020) (0)
Introduction (2011) (0)
99 METABOLIC PHENOTYPING WITH POSITRON EMISSION TOMOGRAPHY FOR PREDICTION OF TUMOR RESPONSE TO THE EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR ERLOTINIB (TARCEVA). (2007) (0)
FDG avidity of metastatic thyroid cancer correlates with the presence of BRAF mutations (2014) (0)
Characterization of a peridiaphragmatic artifact in 18F-FDG-PET/CT and its impact on quantitative analysis in cancer of the gastroesophageal junction (2011) (0)
In vitro and in vivo imaging of irradiation induced changes in PARP1 expression in oral cancer cell lines (2016) (0)
EP-1256 Influence of PET-imaging during treatment planning on outcome in meningioma patients (2019) (0)
FDG-PET is more accurate than CT at assessing early treatment response to neoadjuvant therapy in soft tissue sarcomas (2008) (0)
Preparation of 18F-labeled thymidine analogs using click chemistry (2006) (0)
Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET (2018) (0)
Quantification of glucose metabolic activity of human tumor xenografts in mice (2007) (0)
Radiation treatment to the neck is significantly associated with diffusely increased thyroid FDG-uptake (2006) (0)
Insulin-like growth factor-1 for amelioration and prevention of radiation-induced kidney dysfunction. (2005) (0)
18f-Rhpsma-7 Positron Emission Tomography (PET) for the Detection of Biochemical Recurrence after Primary Radiation Therapy of Prostate Cancer (2019) (0)
Prediction o f R esponse t o P reoperative C hemotherapy i n Gastric C arcinoma b y M etabolic I maging: Results o f a P rospective T rial (2003) (0)
MP09-16 18F-RHPSMA7 POSITRON EMISSION TOMOGRAPHY FOR THE DETECTION OF BIOCHEMICAL RECURRENCE OF PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY (2019) (0)
Correlation of 12 week PSA-response after 177Lu-PSMA radioligand therapy, baseline tumor burden and overall survival in mCRPC (2019) (0)
Monitoring deoxyglucose treatment with FDG and FLT PET (2007) (0)
PET imaging of recurrent brain tumors using 18F-FACBC (2019) (0)
Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrent prostate cancer (2020) (0)
Tumor glucose utilization predicts response to epidermal growth factor receptor kinase inhibitors (2006) (0)
, PhD in Vivo PeT assay of Tumor glutamine Flux and Metabolism : InHuman Trial of 18 F-( 2 S , 4 R )-4-Fluoroglutamine 1 (2018) (0)
1116 POSTER The Influence of the Combined Treatment With Vadimezan (ASa 404) and Taxol on the Growth of U251 Glioblastoma Xenografts (2011) (0)
Patterns of Inguinal Lymph Node Involvement in Anal Cancer - a Detailed PET-Imaging Based Analysis (2019) (0)
Does a p53 Inhibitor Protect Mice Against the Toxicity of High-Dose Abdominal Radiotherapy? (2005) (0)
464 Molecular imaging of therapy response (2010) (0)
326: Positron Emission Tomography Using 11C-Choline in Urothelial Cancer (2004) (0)
Changes in tumor invasiveness in response to src-kinase inhibition monitored by PET with radiolabeled RGD-peptides (2008) (0)
C 16 Development and Preclinical Evaluation of the New Pan-Somatostatin PET Imaging Probe 68 Ga-DOTA-SOM 230 ( SOMscan ® ) (2012) (0)
PET and PET-CT in Treatment Response Evaluation: Overview (2021) (0)
Development of 64Cu- and 68Ga-somatostatin receptor antagonists for improved PET imaging (2011) (0)
Tumor Imaging with Special Emphasis on the Role of Positron Emission Tomography in Radiation Treatment Planning (2009) (0)
Using a CCK2R targeted near-infrared fluorescent probe to aid in intraoperative identification of loco-regional metastasis of medullary thyroid cancer (2014) (0)
for Detection of Bone Marrow Involvement in Children and Adolescents With Hodgkin's Lymphoma (2011) (0)
MP13-15 68GA-PSMA-11 PET/MPMRI FOR DETECTION OF PRIMARY PROSTATE CANCER IN PREVIOUSLY NEGATIVE-BIOPSIED MEN (2020) (0)
Quantitative autoradiographic (QAR) evaluation of bombesin receptor (GRPR) expression in normal and malignant tissue (2014) (0)
Radionuclide Therapy : A Pilot Study Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor (2014) (0)
IMT-SPECT in gliomas: correlation with survival and consequences for target volume definition (2001) (0)
EP-0991 MYOCARDIAL PERFUSION DEFECTS FOLLOWING RADIOTHERAPY FOR BREAST CANCER DETECTED BY 99MTC-MIBI-SPECT/CT (2012) (0)
18F-misonidazole Pet Tumor Hypoxia Imaging During Chemoradiation Therapy For HNSCC - Correlation To Outcome (2014) (0)
Comparative analysis of various endpoints in in-vivo experiments in radiation-induced neural function disorder (2005) (0)
How does the number of lesions analyzed impact response assessment with PERCIST in breast cancer (2015) (0)
Monitoring Prostate Cancer Treatment Response to Radiation Therapy and Androgen Deprivation With Novel Radiolabeled and Dual-Labeled Gastrin-Releasing Peptide Receptor (GRPr) Antagonists. (2016) (0)
550IMT-spect and FDG-pet in the 3-D radiation treatment planning for gliomas (1996) (0)
RADIATION-INDUCED DEFECTS IN MYOCARDIAL PERFUSION AFTER THERAPY FOR LEFT-SIDED BREAST CANCER EVALUATED WITH 99 MTC-MIBI-SPECT/CT (2011) (0)
Preferred blood-brain transfer of O-(2-[18F]fluoroethyl)-D-tyrosine (D-FET) into the porcine brain (2007) (0)
Feasibility of intraoperative fluorescence imaging of squamous cell carcinoma of the oral cavity using an optical PARP1 inhibitor (2015) (0)
Positron E mission T omography i n N on-Small-Cell L ung Cancer: P rediction o f R esponse t o C hemotherapy b y Quantitative A ssessment o f G lucose U se (2003) (0)
Abstract A062: Using CA19-9 as a translational biomarker for sLea targeted agents MVT-5873 and MVT-1075 in cancer (2018) (0)
TU-C-217BCD-01: Where Molecular Imaging Is Taking Us (2012) (0)
UvA-DARE ( Digital Academic Repository ) FDG PET and PET / CT : EANM procedure guidelines for tumour PET imaging : version 1 . 0 (2018) (0)
The value of 18F-FDG PET as a predictor of survival in patients with gastro-oesophageal junction (GEJ) adenocarcinoma (2021) (0)
OC-0386 A PET-based patterns of failure analysis in the context of contouring guidelines in anal cancer (2019) (0)
43 poster: Dynamics of Hypoxia in Head and Neck Cancer During Chemoradiotherapy Evaluated with [18]F-Fluoromisonidazole PET (2010) (0)
The IR evolution in oncology : tools , treatments , guidelines The (2016) (0)
Surveillance of Cancer Patients with Imaging: Self-Evident or Evidence-Based? (2013) (0)
Correlation of 18F-DOPA PET to the genotype of paragangliomas and pheochromocytomas (2012) (0)
Cell surface expression of an engineered antibody as a PET reporter gene for in vivo PET imaging (2008) (0)
Improved pharmacokinetics of [18F]RGD‐peptides by serine‐conjugation (2001) (0)
FDG-PET Is An Independent Predictor for Survival in Primary Central Nervous System Lymphoma (2011) (0)
Molecular Imaging of Prostate Cancer 1 (2015) (0)
Targeted COX-2 and EGFR TK inhibition in advanced non-small cell lung cancer. (2006) (0)
Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: A multicenter retrospective study. (2020) (0)
O-(2-(F-18)fluorethyl)-L-tyrosin: A practicable aminoacid tracer for tumour volume definition by means of positron-emission-tomography in ZNS tumours (2005) (0)
LB4 Positron emission tomography using carbon-11 choline (2004) (0)
Accuracy of 18F-fluoroethyltyrosine PET for detecting high grade glioma recurrence: size matters (2020) (0)
NCOG-16. A PILOT STUDY OF COGNITIVE FUNCTIONS, APOE AND AMYLOID IMAGING IN GLIOMA PATIENTS (2017) (0)
An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients (2016) (0)
Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1) (2016) (0)
CT-Based Radiomics Can Improve the Prediction of Recurrent Prostate Cancer-Positive Lymph Nodes (2019) (0)
The Response of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Cell Lines on Standard Therapy and Treatment with an Experimental Alpha-Particle Emitter Immunoconjugate Targeting EGFR (Bi-213-Cetuximab) (2019) (0)
161 The assistance of PET and MRI in 3-D radiation treatment planning for primary brain tumors (1995) (0)
A theranostic approach for CAR-T cell therapy. (2022) (0)
[Molecular imaging in cancer therapy]. (2010) (0)
Reply: Evidence-Based Assessment of PET in Germany (2012) (0)
Prospective evaluation of FDG-PET for prediction of response and survival in AEG I/II (uT3cNany cM0) (2006) (0)
The Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small Cell Lung Cancer (2014) (0)
Imaging tumor metabolism after RET-inhibitor therapy: Towards an early readout of a novel treatment tool (2008) (0)
Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer. (2015) (0)
Biological imaging in radiation treatment planning for brain tumours (2004) (0)
Is response classification with PERCIST in stage IV breast cancer influenced by the number of lesions assessed (2015) (0)
Glucose metabolic phenotyping and prediction of tumor grade in soft tissue and bone tumors by 18F-FDG PET imaging (2009) (0)
Reproducibility of microPET and bioluminescence imaging in a xenograft model (2007) (0)
Prediction of response to epidermal growth factor receptor kinase inhibitor (erlotinib) in advanced NSCLC by PET/CT: A prospective study (2008) (0)
Evaluation of iPARP1 as an intraoperative imaging agent (2014) (0)
Alterations of cortical glucose metabolism in limbic encephalitis resembling Alzheimer's disease on FDG PET (2009) (0)
PO-0874: Development of a prognostic model for patients with high-grade meningioma - the ELSA study (2020) (0)
Localizing sites of disease in patients with rising PSA up to 1 ng/mL following prostatectomy: how much information can conventional imaging provide? (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Wolfgang Andreas Weber?

Wolfgang Andreas Weber is affiliated with the following schools:

Wolfgang Andreas Weber's Academic­Influence.com Rankings

Why Is Wolfgang Andreas Weber Influential?

Wolfgang Andreas Weber's Published Works

Published Works

What Schools Are Affiliated With Wolfgang Andreas Weber?

Wolfgang Andreas Weber's AcademicInfluence.com Rankings